R&D | June 10, 2026
FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Strategic shift from Italy to India strengthens supply chain resilience, expands capacity and enhances sustainability for the growing global UDCA market
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
